Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06051721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06051721 · ClinicalTrials.gov record · last posted 2026-08-13

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

Name: A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) — clinical trial record (NCT06051721)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 2

SponsorCybin IRL Limited

Started2024-05-10

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.

Protocol amendment history 1 change detected by DataLookout

2026-08-14

Trial completed

Trial Details

NCT Number	NCT06051721
Lead Sponsor	Cybin IRL Limited Collaborators: Worldwide Clinical Trials
Conditions	Generalized Anxiety Disorder
Enrollment	36 participants
Start Date	2024-05-10
Primary Completion	2025-10-14 (estimated)
Study Completion	2026-08-05 (estimated)
Updated on ClinicalTrials.gov	2026-08-13